Literature DB >> 22425136

Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test.

Charlotte U Andersen1, Søren Mellemkjær, Ole Hilberg, Jens Erik Nielsen-Kudsk, Ulf Simonsen, Elisabeth Bendstrup.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is an important complication to interstitial lung disease (ILD). The aim of the present study was to investigate the prevalence and impact of PH on prognosis and exercise capacity in ILD patients.
METHODS: 212 ILD patients were screened for PH by echocardiography. Criteria for PH were either a tricuspid pressure regurgitation gradient >40 mmHg, a tricuspid annular plane systolic excursion <1.8 cm or right ventricular dilatation. If possible, PH was confirmed by right heart catheterisation. Pulmonary function tests and 6 min walk tests (6MWT) were performed.
RESULTS: 29 patients (14%) had PH, 16 (8%) had mild and 13 (6%) had severe PH (mean pulmonary artery pressure ≥ 35 mmHg). Compared to patients without PH, lung function parameters were lower in PH patients, a larger proportion had idiopathic pulmonary fibrosis (IPF) (41 vs 21%, p = 0.006), and the hazard ratio for death was 8.5 (95% CI: 4-17). After correction for lung function parameters and the presence of IPF, 6MWT was significantly lower in patients with PH compared to non-PH patients (difference ± SEM: 58 ± 22 m, p = 0.01).
CONCLUSIONS: PH occurred in 14% of a cohort of patients with ILD and was associated to IPF and lower lung function parameters. Mortality was markedly higher in PH patients, and the presence of PH reduced 6MWT independently of lung function and the presence of IPF. The present results emphasize the need for intensified treatment of patients with ILD and PH.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22425136     DOI: 10.1016/j.rmed.2012.02.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  25 in total

1.  Interstitial lung disease in a child with antisynthetase syndrome.

Authors:  Don Hayes; Peter B Baker; Heidi M Mansour; Mark E Peeples; Kathleen K Nicol
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

2.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

3.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 4.  Clinical physiology and sleep: insights from the European Respiratory Society Congress 2017.

Authors:  Isaac Almendros; Andrea Crespo; Olga Tura-Ceide; Maria R Bonsignore
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

5.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

6.  Pulmonary hypertension in patients with interstitial pneumonia with autoimmune features.

Authors:  Bashar N Alzghoul; Robert Hamburger; Thomas Lewandowski; Brandon Janssen; Daniel Grey; Wei Xue; Ali Ataya; Hassan Alnuaimat; Diana C Gomez-Manjarres; Divya Patel; Raju Reddy
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

Review 7.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

8.  Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Authors:  Hilary F Armstrong; P Christian Schulze; Matthew Bacchetta; Wilawan Thirapatarapong; Matthew N Bartels
Journal:  Respirology       Date:  2014-05-06       Impact factor: 6.424

9.  Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?

Authors:  Kamonpun Ussavarungsi; Augustine S Lee; Charles D Burger
Journal:  Oman Med J       Date:  2016-09

Review 10.  A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Authors:  Gerald Maarman; Sandrine Lecour; Ghazwan Butrous; Friedrich Thienemann; Karen Sliwa
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.